Last $10.71 USD
Change Today +0.26 / 2.49%
Volume 168.0K
PETX On Other Exchanges
As of 5:20 PM 10/21/14 All times are local (Market data is delayed by at least 15 minutes).

aratana therapeutics inc (PETX) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/21/13 - $28.16
52 Week Low
10/2/14 - $9.20
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

aratana therapeutics inc (PETX) Related Businessweek News

View More BusinessWeek News

aratana therapeutics inc (PETX) Details

Aratana Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on the licensing, acquisition, development, and commercialization of biopharmaceutical products for cats, dogs, and other companion animals worldwide. Its product portfolio includes approximately 15 product candidates consisting of small molecule pharmaceuticals and large molecule biologics that target various opportunities in serious medical conditions in pets. The company develops AT-001, a prostaglandin E receptor 4 antagonist to treat the pain and inflammation associated with osteoarthritis in dogs, as well as for the management of pain in cats; AT-002, a ghrelin agonist for inappetence in cats and dogs; and AT-003, a bupivacaine liposome injectable suspension for the treatment of post-operative pain in cats and dogs. It also develops AT-004, a monoclonal antibody (MAB) used in the treatment of canine B-cell lymphoma; and AT-005, a MAB for the treatment of canine T-cell lymphoma in pets. The company was founded in 2010 and is headquartered in Kansas City, Kansas.

25 Employees
Last Reported Date: 03/26/14
Founded in 2010

aratana therapeutics inc (PETX) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $425.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $50.7K
Chief Development Officer
Total Annual Compensation: $286.1K
Chief Commercial Officer
Total Annual Compensation: $270.6K
Chief Scientific Officer
Total Annual Compensation: $225.0K
Compensation as of Fiscal Year 2013.

aratana therapeutics inc (PETX) Key Developments

Aratana Therapeutics and Atopix Complete Global Licensing Agreement for Development and Commercialization of Novel Atopic Dermatitis Program

Aratana Therapeutics, Inc. and Atopix Therapeutics Ltd. announced the completion of a global licensing agreement for the development and commercialization of a novel oral CRTH2 antagonist for animal health indications. The decision to enter into this licensing agreement, which was previously announced, was based on favorable results from early de-risking studies performed under the now-completed option agreement between the two companies. Under the license agreement, Aratana agreed to develop and seek approval for the use of the product in atopic dermatitis, focusing initially on developing the product for dogs.

Aratana Therapeutics Mulls Acquisitions

Aratana Therapeutics, Inc. (NasdaqGM:PETX) is looking for acquisitions. Aratana Therapeutics, Inc. announced a third public offering of its stock and plans to use a portion of the proceeds to expand its commercial infrastructure in anticipation of future product launches. Aratana Therapeutics, Inc. also may use the money to in-license or acquire additional technologies or businesses and continue development of its current technologies.

Aratana Therapeutics, Inc. Reports Positive Effectiveness Data from Pilot Field Study of Bupivacaine Extended-Release Injectable Suspension (AT-003)

Aratana Therapeutics, Inc. announced positive results from its pilot field study of its Bupivacaine Extended-Release Injectable Suspension (AT-003) for managing post-operative pain in cats and dogs following surgery. In the study, which enrolled 46 client-owned dogs, AT-003 demonstrated significantly greater pain control over time following knee surgery compared to placebo. Based on these results, Aratana anticipates discussing the design of the pivotal field effectiveness with the FDA in the coming weeks and continues to anticipate the first FDA approval in 2016. Pain levels were assessed repeatedly for 72 hours following knee surgery using the Glasgow Composite Measure Pain Scale, short form (CMPS-SF), a well-accepted and reliable metric for measuring acute pain in dogs. The data show that treatment with AT-003 resulted in a statistically significant reduction in mean total pain scores over time compared to placebo (p<0.05). Aratana also analyzed the data for "no pain intervention post-surgery". The percent of patients treated with AT-003 which did not require additional pain medication was statistically greater (p<0.05) compared to placebo at each 24-hour time interval (0-24h, 24-48h, 48-72h) for up to 72 hours after surgery.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PETX:US $10.71 USD +0.26

PETX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Kindred Biosciences Inc $9.02 USD +0.10
View Industry Companies

Industry Analysis


Industry Average

Valuation PETX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 501.8x
Price/Book 1.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 461.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ARATANA THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at